October’s top stories: NIH found new target proteins for anti-malaria drugs, NCI discovered new way to combat cancer
NIH found new target proteins for anti-malaria drugs A new study funded by the National Institutes of Health (NIH) in…
All articles by Srivari Aishwarya
Srivari Aishwarya
-
-
UK MHRA recommends Roche’s new immunotherapy atezolizumab for bladder cancer
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given a positive scientific opinion for Roche’s new immunotherapy, atezolizumab,…
-
SRI wins $150m contract to accelerate production of HIV-prevention products
US-based SRI International has been contracted by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and…
-
UK’s CMA fines Pfizer and Flynn Pharma nearly £90m for unfair pricing of epilepsy drug
Pfizer and Flynn Pharma have been fined nearly £90m by the Competition and Markets Authority (CMA) for charging unfair prices…
-
New study reveals 75% of critically ill patients in Latin America are malnourished
A study conducted by German healthcare company Fresenius Kabi has revealed that more than 75% of critically ill patients in Latin…
-
GSK submits biologics licence application to FDA for shingles vaccine
GlaxoSmithKline (GSK) has submitted a biologics licence application to the US Food and Drug Administration (FDA) for approval of its…
-
HMT to support NIA’s study on brain metabolomic profiles in Alzheimer’s
Human Metabolome Technologies (HMT) has been contracted by the National Institute on Aging (NIA) to study brain metabolomic profiles in…
-
UK researchers explore use of nanotechnology to improve HIV drug therapies
Researchers at the University of Liverpool, UK, are exploring the use of nanotechnology to improve administration and availability of drug…
-
Elsevier selects four start-up companies for The Hive incubator project
Elsevier has selected four start-up companies for its new incubator project, The Hive, for biotech and pharmaceutical start-up firms.Arctic Pharma,…
-
Milo Biotechnology receives orphan drug designation for AAV1-FS344 to treat inclusion body myositis
Milo Biotechnology has secured Orphan Drug designation for its AAV1-FS344 from the Federal Drug Administration’s (FDA) Office of Orphan Products…